Foghorn Therapeutics Inc. filings document a clinical-stage biotechnology issuer with common stock listed on the Nasdaq Global Market under FHTX. The company’s current-event filings cover financial results, Regulation FD investor presentations, oncology pipeline disclosures for FHD-909 and selective CBP, EP300 and ARID1B degrader programs, and collaboration-related revenue.
Proxy and 8-K filings also address annual-meeting voting matters, board and executive governance, officer appointments, compensatory arrangements, material agreements, capital-structure disclosures and security-registration details tied to the company’s common stock and financing activity.
Foghorn Therapeutics Inc. (FHTX) is the subject of a joint initial ownership report by Mark N. Lampert, listed as a 10% owner, and affiliated investment entities in a Section 13(d) group collectively beneficially owning more than 10% of common stock. As of October 1, 2026, reported Pre-Funded, Series 1 and Series 2 Warrants were exercisable for 5,840,979, 1,835,659 and 1,835,659 shares, respectively. Each class is immediately exercisable subject to a 9.99% beneficial-ownership limit; the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interests.
Foghorn Therapeutics Inc. (FHTX) reports that Biotechnology Value Fund, L.P. beneficially owned 4,494,462 shares (approximately 7.6%), Biotechnology Value Fund II, L.P. 3,232,448 shares (approximately 5.4%), and Biotechnology Value Trading Fund OS LP 619,258 shares (approximately 1.0%) as of the close of business on October 1, 2026. The percentages use 59,385,315 shares outstanding as of July 31, 2026.
BVF Partners L.P., BVF Inc. and Mark N. Lampert each may be deemed to beneficially own 8,507,000 shares (approximately 14.3%), including shares held in a managed account; these overlapping attributions are not separate blocks to add. The reporting persons and the managed account also held pre-funded warrants exercisable for 5,937,278 shares and Series 1 and Series 2 warrants exercisable for 1,862,891 shares each. The 9.99% blockers prohibited exercise of all such warrants as of October 1, 2026.
Foghorn Therapeutics Inc. (FHTX) and Eli Lilly decided not to advance FHD-909 into the clinical development expansion phase after reviewing Phase 1 trial data. The collaboration also will not advance the selective SMARCA2 degrader program, and further collaboration activities are not anticipated.
Following a September 30, 2026 board-approved reprioritization, Foghorn plans to focus on its selective EP300 degrader, immunology and inflammation program, selective CBP degrader, induced proximity platform and other proprietary programs. The company announced an approximately 40% workforce reduction, expected to be substantially complete in the fourth quarter of 2026, leaving approximately 65 full-time employees. It estimates approximately $2.3 million in charges, all anticipated as future cash expenditures, primarily one-time severance and benefit costs expected in the fourth quarter of 2026. The changes are expected to extend cash runway into the second half of 2029.
Foghorn Therapeutics Inc. reported Q2 2026 collaboration revenue of $16.1 million, up from $7.6 million a year earlier, driven largely by a $14.2 million cumulative catch-up adjustment on its Eli Lilly collaboration as the research term approaches scheduled expiration in December 2026. Research and development expenses were $18.5 million and general and administrative expenses $6.4 million, both lower than Q2 2025, reflecting reduced spending on Lilly-partnered programs, discontinued FHD‑286 activities and lower facility costs after relocating to Watertown, Massachusetts.
Net loss for the quarter narrowed to $7.2 million, or $0.10 per share, from $17.9 million, or $0.28 per share, in Q2 2025. For the first six months of 2026, revenue was $19.3 million and net loss $27.1 million. Cash, cash equivalents and marketable securities totaled $167.6 million as of June 30 2026, and management states this balance is expected to fund operating and capital needs for at least 12 months, though additional financing will be required over time to support ongoing development of the Gene Traffic Control® platform and pipeline, including the SMARCA2 program FHD‑909 being developed with Lilly.
In January 2026, Foghorn raised approximately $50.0 million in gross proceeds through a direct offering of common stock, pre‑funded warrants, and two series of equity‑classified warrants, while deferred revenue related to the Lilly collaboration was $229.8 million remaining to be recognized over the development period.
Foghorn Therapeutics reported Q2 2026 results alongside a broad pipeline update in chromatin biology. Lead asset FHD‑909, a first‑in‑class selective SMARCA2 inhibitor partnered with Lilly, is advancing through a first‑in‑human Phase 1 dose‑escalation trial focused on SMARCA4‑mutant non‑small cell lung cancer. Pending successful Phase 1 dose escalation, Foghorn and Lilly anticipate evaluating FHD‑909 in combination studies in NSCLC with pembrolizumab. Selective EP300 degraders for hematologic malignancies and prostate cancer and a selective CBP degrader (FHT‑171) for ER+ breast and EP300‑mutant cancers are progressing preclinically, with INDs targeted in 2027. A novel oral small molecule in immunology and inflammation and a first‑in‑class ARID1B degrader for ARID1A‑mutant solid tumors are also being advanced toward 2027 INDs, while the CBP program timeline has been delayed by an operational issue at a third‑party contract research organization.
Collaboration revenue for the quarter was $16.1 million versus $7.6 million a year earlier, driven by a cumulative catch‑up adjustment under the Lilly collaboration. Research and development expenses were $18.5 million and general and administrative expenses were $6.4 million. Net loss was $7.2 million compared with $17.9 million in Q2 2025. Cash, cash equivalents and marketable securities totaled $167.6 million at June 30, 2026, providing cash runway into the first half of 2028.
Foghorn Therapeutics Inc. director Thomas J. Lynch Jr. received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, conditioned on his continued service on the board of directors, and expire on June 23, 2036. Following this grant, he holds options for 28,000 underlying shares directly.
Foghorn Therapeutics Inc. director Stuart Duty received a grant of stock options to buy 28,000 shares of Common Stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, subject to his continued board service, and expire on June 23, 2036. Following this grant, Duty holds 28,000 stock options directly.
Foghorn Therapeutics director Scott Biller received a stock option grant covering 28,000 shares of common stock at an exercise price of $4.08 per share. The option was granted as compensation and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. Following this award, Biller holds 28,000 stock options directly.
Foghorn Therapeutics Inc. director Neil Gallagher received a grant of stock options as part of his compensation. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. After this grant, he holds 28,000 stock options directly, which are scheduled to expire on June 23, 2036. This is a compensation-related award, not an open-market purchase or sale.
Foghorn Therapeutics director Michael Mendelsohn received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options were awarded as compensation and give him the right to buy shares at that price in the future.
The options vest in full on the first anniversary of the grant date, as long as he continues to serve on the board of directors. After this grant, he holds 28,000 stock options directly, with an expiration date in 2036, providing long-term equity-based incentives tied to the company’s share performance.